Non-melanoma Skin Cancer Market
Non-melanoma Skin Cancer Market Study by Radiation Therapy, Chemotherapy, and Photodynamic Therapy for Basal Cell Carcinoma and Squamous Cell Carcinoma from 2024 to 2034
Analysis of Non-melanoma Skin Cancer Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Non-melanoma Skin Cancer Market Outlook from 2024 to 2034
The non-melanoma skin cancer market is estimated to be valued at US$ 5,068.7 million in 2024. The market is expected to register a CAGR of 5.7% from 2024 to 2034. The market is expected to reach a value of US$ 8,859.6 million by 2034.
The number of patients with skin cancer is rising, necessitating skin cancer treatment. The rise in temperatures as a result of global warming is a key reason for the increase in the number of skin cancer patients. The non-melanoma variant of skin cancer is afflicting an increasing number of people, and thus, the market for non-melanoma skin cancer is witnessing a surge in demand.
Key Market Growth Drivers
Unlike melanomas, non-melanoma skin cancer works slowly and thus there is more scope for treatment. With preventive healthcare measures being implemented, non-melanoma skin cancers are being detected at early stages and treatment is being administered for a prolonged period. As such, the results of the treatment are positive, benefitting the market.
Healthcare institutions’ drive awareness about skin cancers among people, which is being aided by government campaigns. With an eye towards improving rates of cancer survival, there is encouragement from the government for regular checkups and treatment. Government initiatives are also helping the research and development activities in the non-melanoma skin cancer industry.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 5,068.7 million |
| Forecasted Market Value (2034F) | US$ 8,859.6 million |
| Global Market Growth Rate (2024 to 2034) | 5.7% CAGR |
| Radiation Therapy Segment Growth Rate (2024 to 2034) | 5.6% |
| Basal Cell Carcinoma Segment Growth Rate (2024 to 2034) | 6.8% |
| North America Market Share (2024) | 58.0% |
| East Asia Market Share (2024) | 0.8% |
| Key Companies Profiled | Amgen Inc.; Regeneron Pharmaceuticals Inc.; Almirall; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Hoffmann-La Roche Ltd; GlaxoSmithKline Plc; Merck & Co., Inc.; Novartis AG; Eli Lilly and Company; Sun Pharmaceutical Industries Ltd. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Factors are Driving the Non-melanoma Skin Cancer Market?
“Convenient Radiation Therapy Machines Ease Treatment Processes for Non-melanoma Skin Cancer Patients”
Radiation therapy is one of the most popular types of treatment when it comes to non-melanoma skin cancer. With the rising number of people undergoing radiation therapy, market players are focusing on producing machines that can increase the comfort of patients. The development of portable radiation machines ensures that patients do not have to strictly be confined to a singular bed while receiving treatment.
“Integration of New Technologies into Devices Used for Treatment”
Therapies used for the treatment of non-melanoma skin cancer are getting updated with the integration of cutting-edge technologies. Newly developed therapies such as stereotactic body radiation therapy (SBRT) and spatially fractionated radiation therapy (SFRT) concentrate on minimizing the side effects of the procedure, while general technology like AI is also being implemented for purposes such as diagnostic assistance and quality assurance. Thus, the integration of technology is making sure the market demand remains fresh.
What are the Challenges Encountered by Market Players?
“Aversion Towards Side Effects, as well as the High Price Involved, Makes People Skeptical of Non-melanoma Skin Cancer Treatment”
The treatments for non-melanoma skin cancer, such as radiation therapy and chemotherapy, come with side effects. Hair loss, skin peeling, and anemia are some of the potential side effects of therapies used to treat non-melanoma skin cancer. Thus, despite the necessity of treatment, many people are hesitant about it. The high price of the treatment is another impediment to the growth of the market.
Several market players are coming up with measures to combat these restraints. The development of new forms of therapy is concentrated on minimizing the side effects associated with the treatment. Cheaper treatment options are also being made available with government aid. Nonetheless, the market still has to face significant challenges over the forecast period.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
North America accounts for an overwhelming share of the non-melanoma skin cancer market. Even though the share in the market is predicted to decrease over the forecast period, North America is still a lucrative region in the industry. In 2024, the value of the market in North America is estimated to be US$ 2,941.0 million, for a market share of 58.0%. The market is expected to progress at a CAGR of 2.9% from 2024 to 2034. By 2034, the industry value for North America is projected to reach US$ 3,930.0 million, with a market share of 44.4%.
The non-melanoma skin cancer market in East Asia is expected to progress at a faster pace than in North America. In 2024, the industry share for East Asia is projected to be 0.8%, with a market value of US$ 40.0 million. The market is expected to register a CAGR of 5.6% over the forecast period. By 2034, the market value in East Asia is anticipated to reach US$ 78.0 million, with an increased market share of 0.9%.
What Makes Mexico a Promising Country in the Non-melanoma Skin Cancer Market?
“High Number of Patients with Skin Cancer in Mexico”
| Attribute | Detail |
|---|---|
| Market Value in 2024 | US$ 14.0 million |
| CAGR (2024 to 2034) | 8.1% |
Mexico is set to be one of the most promising countries for the non-melanoma skin cancer industry. While the market value in Mexico is estimated to be US$ 14.0 million in 2024, it is projected to rise at a CAGR of 8.1% over the forecast period. By 2034, the value of the market is forecasted to rise to US$ 29.0 million.
Increased amounts of exposure to the sun have led to a rise in the number of people getting skin cancer in Mexico. With increasing global warming levels, the heat in the external environment is rising and the number of people at risk of skin cancers, both melanoma and non-melanoma, is also surging. Thus, treatment for non-melanoma skin cancer is being increasingly sought in Mexico.
Why is China Emerging as a Lucrative Country for Market Players?
“Considerable Population of China Prone to Cancers, Including Non-melanoma Skin Cancer”
| Attribute | Detail |
|---|---|
| Market Value in 2024 | US$ 27.0 million |
| CAGR (2024 to 2034) | 7.0% |
China is one of the most lucrative Asian countries in the non-melanoma skin cancer industry. The market valuation is anticipated to be US$ 27.0 million in 2024. From 2024 to 2034, the market is expected to progress at a CAGR of 7.0% through 2034. The market valuation is expected to reach US$ 53.0 million by 2034.
China is claimed to be the country with the highest number of cancer patients as well as cancer deaths in Asia. As a result, there is a growing drive to protect the Chinese population from cancer. Treatments like non-melanoma skin cancer therapy are, therefore, receiving a boost in the country in terms of research and public investment.
Category-wise Insights
Radiation therapy is the most common type of therapy administered, with an expected market share of 88.6% in 2024. The second most popular type of therapy is photodynamic therapy, which is expected to account for 8.6% of the market share in 2024. By indication, the basal cell carcinoma segment is leading the market, with an expected industry share of 75.7% in 2024. Squamous cell carcinoma is expected to account for the remaining 24.3%.
Which is the Highly Preferred Mode of Treatment for Non-melanoma Skin Cancer?
“Success of Radiation Therapy in Treatment of All Cancer Types”
| Attribute | Detail |
|---|---|
| Market Share in 2024 | 88.6% |
Radiation therapy leads the treatment type segment, with an anticipated market share of 88.6% in 2024. The product is expected to register a CAGR of 5.6% over the forecast period. By 2034, the share of radiation therapy in the treatment type segment is expected to be 87.4%.
Radiation therapy is the go-to option for many healthcare experts. It has proven itself to be an effective form of treatment for a variety of cancers. The confidence placed in radiation therapy extends to the treatment of non-melanoma skin cancer. Thus, radiation therapy is the dominant form of treatment in the market.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
As a way to make treatments more effective, companies are investing heavily in research and development. Market players are also augmenting research efforts by collaborating with research institutes and universities and providing them financial aid.
Market players are taking advantage of public campaigns to raise awareness of non-melanoma skin cancer. Widespread advertising campaigns are being engineered to increase check-up and treatment numbers.
Key players in the market include Amgen Inc., Regeneron Pharmaceuticals Inc., Almirall, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Eli Lilly and Company, and Sun Pharmaceutical Industries Ltd.
Recent Developments :
- In November 2023, DermaSensor announced that its AI-powered elastic scattering spectroscopy (ESS) device showed positive results in the detection of skin cancers.
- In August 2023, SkinCure Oncology was made available in the American state of Kentucky. SkinCure Oncology provides Image-Guided Superficial Radiation Therapy (Image-Guided SRT), a non-surgical way of treating skin cancers.
- In June 2023, it was announced that Sirnaomics Ltd.’s siRNA treatment for squamous cell carcinoma had advanced to phase 3 of its trial after positive phase 2 results.
Segmentation of Non-melanoma Skin Cancer Market Research
-
By Treatment Type:
- Radiation Therapy
- Chemotherapy
- Photodynamic Therapy
-
By Indication:
- Basal Cell Carcinoma
- Squamous Cell Carcinoma
-
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
-
By Region:
- North America
- Europe
- Latin America
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Background
- 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
- 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment Type
- 5.1. Radiation Therapy
- 5.1.1. External Beam Radiation Therapy
- 5.1.2. Electronic Brachytherapy
- 5.1.3. Superficial Radiation Therapy
- 5.2. Chemotherapy
- 5.3. Photodynamic Therapy
- 5.1. Radiation Therapy
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
- 6.1. Basal Cell Carcinoma
- 6.2. Squamous Cell Carcinoma
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
- 7.1. Hospitals
- 7.2. Ambulatory Surgical Centres
- 7.3. Specialty Clinics
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
- 8.1. North America
- 8.2. Latin America
- 8.3. Western Europe
- 8.4. Eastern Europe
- 8.5. South Asia and Pacific
- 8.6. East Asia
- 8.7. Middle East and Africa
- 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 16. Key Countries Market Analysis
- 17. Market Structure Analysis
- 18. Competition Analysis
- 18.1. Almirall S.A.
- 18.2. Boehringer Ingelheim GmbH
- 18.3. Bristol-Myers Squibb Company
- 18.4. Eli Lilly and Company
- 18.5. Elekta AB
- 18.6. F. Hoffmann-La Roche Ltd.
- 18.7. Merck & Co., Inc.
- 18.8. Novartis AG
- 18.9. Sun Pharmaceutical Industries Ltd.
- 18.10. Varian Medical Systems, Inc.
- 19. Assumptions & Acronyms Used
- 20. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 02: Global Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 03: Global Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 04: Global Market Value (US$ Million) Forecast by End User , 2019 to 2034
Table 05: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 06: North America Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 07: North America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 08: North America Market Value (US$ Million) Forecast by End User , 2019 to 2034
Table 09: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 10: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 11: Latin America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 12: Latin America Market Value (US$ Million) Forecast by End User , 2019 to 2034
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 14: Western Europe Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 15: Western Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 16: Western Europe Market Value (US$ Million) Forecast by End User , 2019 to 2034
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User , 2019 to 2034
Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by End User , 2019 to 2034
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 26: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 27: East Asia Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 28: East Asia Market Value (US$ Million) Forecast by End User , 2019 to 2034
Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by End User , 2019 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 02: Global Market Value (US$ Million) by Indication, 2024 to 2034
Figure 03: Global Market Value (US$ Million) by End User , 2024 to 2034
Figure 04: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 05: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 06: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 07: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 08: Global Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 09: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 11: Global Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 14: Global Market Value (US$ Million) Analysis by End User , 2019 to 2034
Figure 15: Global Market Value Share (%) and BPS Analysis by End User , 2024 to 2034
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User , 2024 to 2034
Figure 17: Global Market Attractiveness by Treatment Type, 2024 to 2034
Figure 18: Global Market Attractiveness by Indication, 2024 to 2034
Figure 19: Global Market Attractiveness by End User , 2024 to 2034
Figure 20: Global Market Attractiveness by Region, 2024 to 2034
Figure 21: North America Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 22: North America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 23: North America Market Value (US$ Million) by End User , 2024 to 2034
Figure 24: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 28: North America Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 31: North America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 32: North America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 33: North America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 34: North America Market Value (US$ Million) Analysis by End User , 2019 to 2034
Figure 35: North America Market Value Share (%) and BPS Analysis by End User , 2024 to 2034
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User , 2024 to 2034
Figure 37: North America Market Attractiveness by Treatment Type, 2024 to 2034
Figure 38: North America Market Attractiveness by Indication, 2024 to 2034
Figure 39: North America Market Attractiveness by End User , 2024 to 2034
Figure 40: North America Market Attractiveness by Country, 2024 to 2034
Figure 41: Latin America Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 42: Latin America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 43: Latin America Market Value (US$ Million) by End User , 2024 to 2034
Figure 44: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 51: Latin America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 54: Latin America Market Value (US$ Million) Analysis by End User , 2019 to 2034
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User , 2024 to 2034
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User , 2024 to 2034
Figure 57: Latin America Market Attractiveness by Treatment Type, 2024 to 2034
Figure 58: Latin America Market Attractiveness by Indication, 2024 to 2034
Figure 59: Latin America Market Attractiveness by End User , 2024 to 2034
Figure 60: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 61: Western Europe Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 62: Western Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 63: Western Europe Market Value (US$ Million) by End User , 2024 to 2034
Figure 64: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 68: Western Europe Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 71: Western Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 74: Western Europe Market Value (US$ Million) Analysis by End User , 2019 to 2034
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User , 2024 to 2034
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User , 2024 to 2034
Figure 77: Western Europe Market Attractiveness by Treatment Type, 2024 to 2034
Figure 78: Western Europe Market Attractiveness by Indication, 2024 to 2034
Figure 79: Western Europe Market Attractiveness by End User , 2024 to 2034
Figure 80: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 81: Eastern Europe Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 82: Eastern Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 83: Eastern Europe Market Value (US$ Million) by End User , 2024 to 2034
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User , 2019 to 2034
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User , 2024 to 2034
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User , 2024 to 2034
Figure 97: Eastern Europe Market Attractiveness by Treatment Type, 2024 to 2034
Figure 98: Eastern Europe Market Attractiveness by Indication, 2024 to 2034
Figure 99: Eastern Europe Market Attractiveness by End User , 2024 to 2034
Figure 100: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 101: South Asia and Pacific Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 102: South Asia and Pacific Market Value (US$ Million) by Indication, 2024 to 2034
Figure 103: South Asia and Pacific Market Value (US$ Million) by End User , 2024 to 2034
Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by End User , 2019 to 2034
Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User , 2024 to 2034
Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User , 2024 to 2034
Figure 117: South Asia and Pacific Market Attractiveness by Treatment Type, 2024 to 2034
Figure 118: South Asia and Pacific Market Attractiveness by Indication, 2024 to 2034
Figure 119: South Asia and Pacific Market Attractiveness by End User , 2024 to 2034
Figure 120: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 121: East Asia Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 122: East Asia Market Value (US$ Million) by Indication, 2024 to 2034
Figure 123: East Asia Market Value (US$ Million) by End User , 2024 to 2034
Figure 124: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 128: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 129: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 131: East Asia Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 134: East Asia Market Value (US$ Million) Analysis by End User , 2019 to 2034
Figure 135: East Asia Market Value Share (%) and BPS Analysis by End User , 2024 to 2034
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by End User , 2024 to 2034
Figure 137: East Asia Market Attractiveness by Treatment Type, 2024 to 2034
Figure 138: East Asia Market Attractiveness by Indication, 2024 to 2034
Figure 139: East Asia Market Attractiveness by End User , 2024 to 2034
Figure 140: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 141: Middle East and Africa Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 142: Middle East and Africa Market Value (US$ Million) by Indication, 2024 to 2034
Figure 143: Middle East and Africa Market Value (US$ Million) by End User , 2024 to 2034
Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by End User , 2019 to 2034
Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by End User , 2024 to 2034
Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User , 2024 to 2034
Figure 157: Middle East and Africa Market Attractiveness by Treatment Type, 2024 to 2034
Figure 158: Middle East and Africa Market Attractiveness by Indication, 2024 to 2034
Figure 159: Middle East and Africa Market Attractiveness by End User , 2024 to 2034
Figure 160: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
Which is the Leading Treatment Type in the Non-melanoma Skin Cancer Market?
Radiation therapy is the leading treatment type in the non-melanoma skin cancer market, with an expected market share of 88.6% in 2024.
What is the Sales Outlook for Non-melanoma Skin Cancer Treatment in 2024?
The sales outlook for non-melanoma skin cancer is likely to be valued at US$ 5,068.7 million in 2024.
What is the Expected Market Demand by 2034?
The demand for non-melanoma skin cancer is projected to reach a market value of US$ 8,859.6 million by the end of 2034.
What is the Growth Projection for the Non-melanoma Skin Cancer Market?
The non-melanoma skin cancer market is projected to rise at a CAGR of 5.7% through 2034.
Who are the Key Players in the Non-melanoma Skin Cancer Market?
Amgen Inc., Regeneron Pharmaceuticals Inc., Almirall, and Boehringer Ingelheim International GmbH are some of the prominent brands in the market.
Non-melanoma Skin Cancer Market